Literature DB >> 27271554

Radiofrequency catheter ablation versus balloon cryoablation of atrial fibrillation: markers of myocardial damage, inflammation, and thrombogenesis.

Bor Antolič1, Andrej Pernat2, Marta Cvijić2, David Žižek2, Matevž Jan3, Matjaž Šinkovec2.   

Abstract

BACKGROUND: Evidence from animal and human studies suggests that cryoablation might be associated with a lesser inflammatory response and activation of coagulation compared with radiofrequency ablation. The study was aimed at comparing the effect of cryoballoon and radiofrequency catheter ablation of paroxysmal atrial fibrillation on markers of myocardial damage, inflammation, and activation of coagulation.
METHODS: Forty-one patients received either cryoballoon (n = 23) or radiofrequency (n = 18) ablation of atrial fibrillation. We measured troponin I, high-sensitivity CRP, and interleukin 6 at baseline from the cubital vein, and from the right and left atrium before and after ablation, and from the cubital vein the following day. Prothrombin fragments 1 + 2, soluble P‑selectin, and D‑dimer were measured before and after ablation from both atria.
RESULTS: We observed higher troponin I release in the cryoballoon than in the radiofrequency group (7.01 mcg/l (interquartile range [IQR]: 5.30-9.09) vs 2.32 mcg/l (IQR: 1.45-2.98), p < 0.001). The levels of inflammatory markers (high-sensitivity CRP and interleukin 6) in the two groups were comparable, as were the levels of markers of coagulation activation. Procedure duration, fluoroscopy times, and mid-term success (23 months, IQR 7-32) of the two groups were also comparable.
CONCLUSIONS: Cryoballoon ablation of atrial fibrillation causes more significant myocardial damage, that is, more extensive ablation lesions, compared with radiofrequency catheter ablation. However, no major differences between these two ablation techniques with regard to the inflammatory response and activation of the coagulation system were observed.

Entities:  

Keywords:  Atrial fibrillation; Coagulation; Cryoablation; Inflammation; Radiofrequency ablation

Mesh:

Substances:

Year:  2016        PMID: 27271554     DOI: 10.1007/s00508-016-1002-0

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  26 in total

1.  IgM colocalises with complement and C reactive protein in infarcted human myocardium.

Authors:  P A J Krijnen; C Ciurana; T Cramer; T Hazes; C J L M Meijer; C A Visser; H W M Niessen; C E Hack
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

2.  Cellular damage, platelet activation, and inflammatory response after pulmonary vein isolation: a randomized study comparing radiofrequency ablation with cryoablation.

Authors:  Claudia Herrera Siklódy; Thomas Arentz; Jan Minners; Laurence Jesel; Christian Stratz; Christian M Valina; Reinhold Weber; Dietrich Kalusche; Florence Toti; Olivier Morel; Dietmar Trenk
Journal:  Heart Rhythm       Date:  2011-09-13       Impact factor: 6.343

3.  Normal pulmonary veins anatomy is associated with better AF-free survival after cryoablation as compared to atypical anatomy with common left pulmonary vein.

Authors:  Maciej Kubala; Jean-Sylvain Hermida; Georges Nadji; Serge Quenum; Sarah Traulle; Geneviève Jarry
Journal:  Pacing Clin Electrophysiol       Date:  2011-03-21       Impact factor: 1.976

Review 4.  Inflammation in the genesis and perpetuation of atrial fibrillation.

Authors:  Mads D M Engelmann; Jesper Hastrup Svendsen
Journal:  Eur Heart J       Date:  2005-06-23       Impact factor: 29.983

5.  Localisation of C reactive protein in infarcted tissue sites of multiple organs during sepsis.

Authors:  A Baidoshvili; R Nijmeijer; W K Lagrand; C E Hack; H W M Niessen
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

6.  C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation?

Authors:  Naoyuki Sata; Naokazu Hamada; Takashi Horinouchi; Shigeru Amitani; Takuya Yamashita; Yukinori Moriyama; Kenkichi Miyahara
Journal:  Jpn Heart J       Date:  2004-05

Review 7.  Inflammation markers in point-of-care testing (POCT).

Authors:  Albrecht Pfäfflin; Erwin Schleicher
Journal:  Anal Bioanal Chem       Date:  2008-12-23       Impact factor: 4.142

8.  Trans-septal catheterization for radiofrequency catheter ablation of cardiac arrhythmias. Results and safety of a simplified method.

Authors:  R De Ponti; M Zardini; C Storti; M Longobardi; J A Salerno-Uriarte
Journal:  Eur Heart J       Date:  1998-06       Impact factor: 29.983

9.  Protracted CRP elevation after atrial fibrillation ablation.

Authors:  James M McCabe; Lisa M Smith; Zian H Tseng; Nitish Badhwar; Byron K Lee; Randall J Lee; Melvin M Scheinman; Jeffrey E Olgin; Gregory M Marcus
Journal:  Pacing Clin Electrophysiol       Date:  2008-09       Impact factor: 1.976

10.  Circumferential pulmonary vein isolation with the cryoballoon technique results from a prospective 3-center study.

Authors:  Thomas Neumann; Jürgen Vogt; Burghard Schumacher; Anja Dorszewski; Malte Kuniss; Hans Neuser; Klaus Kurzidim; Alexander Berkowitsch; Marcus Koller; Johannes Heintze; Ursula Scholz; Ulrike Wetzel; Michael A E Schneider; Dieter Horstkotte; Christian W Hamm; Heinz-Friedrich Pitschner
Journal:  J Am Coll Cardiol       Date:  2008-07-22       Impact factor: 24.094

View more
  2 in total

Review 1.  Comparison of catheter ablation for paroxysmal atrial fibrillation between cryoballoon and radiofrequency: a meta-analysis.

Authors:  Chao-Feng Chen; Xiao-Fei Gao; Xu Duan; Bin Chen; Xiao-Hua Liu; Yi-Zhou Xu
Journal:  J Interv Card Electrophysiol       Date:  2017-01-07       Impact factor: 1.900

2.  Effects of different ablation strategies on long-term left atrial function in patients with paroxysmal atrial fibrillation: a single-blind randomized controlled trial.

Authors:  Ling You; Lixia Yao; Bolun Zhou; Lili Jin; Honglin Yin; Jinglan Wu; Guangli Yin; Ying Yang; Chenfeng Zhang; Yue Liu; Ruiqin Xie
Journal:  Sci Rep       Date:  2019-05-22       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.